Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
4.000
+0.130 (3.36%)
Dec 20, 2024, 4:00 PM EST - Market closed
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
96
Market Cap
172.69M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
Dec 31, 2021 | 5.66M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKYTX News
- 8 hours ago - The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc - Accesswire
- 1 day ago - Kyverna Therapeutics Inc. Is Being Sued For Violating Securities Laws And Affected Investors Are Invited To Contact The Schall Law Firm - Accesswire
- 1 day ago - SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - GlobeNewsWire
- 2 days ago - Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights - KYTX - PRNewsWire
- 2 days ago - The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc. - Accesswire
- 3 days ago - DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - PRNewsWire
- 4 days ago - Kyverna Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Assist The Schall Law Firm - Accesswire
- 5 days ago - The Schall Law Firm Urges Stockholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc - Accesswire